NCT03157167View on ClinicalTrials.gov

An Evaluation of Tc 99m Tilmanocept by Intravenous (IV) and Subcutaneous (SC) Injection in Kaposi Sarcoma (KS)

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

December 1, 2017

Primary Completion Date

November 5, 2019

Study Completion Date

March 30, 2020

Conditions
Kaposi SarcomaHIV Infections
Interventions
DRUG

Tc99m-tilmanocept

Tilmanocept is a radiotracer that accumulates in macrophages by binding to a mannose binding receptor that resides on the surface.

Trial Locations (1)

94143

Zuckerberg San Francisco General Hospital, San Francisco

Sponsors
All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

National Cancer Institute (NCI)

NIH

lead

Navidea Biopharmaceuticals

INDUSTRY